SCHEMBL14960417

SCHEMBL14960417

CN(O)C1CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8011374 0.97
SCHEMBL15265876 0.97
SCHEMBL2152599 0.86
Hydrochloric Acid SCHEMBL1041115 0.83
Methyl Alcohol SCHEMBL2130090 0.73 PHGDH (0.42)
SCHEMBL22851843 0.73
SCHEMBL3441569 0.73
SCHEMBL284507 0.72
SCHEMBL22837457 0.72 ADH1A (0.46)
SCHEMBL12036975 0.72 ADH1A (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4602020-A1 ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING Ecolab USA, Inc. (US) 2025-08-20 EP claimed
US-20240141131-A1 ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING ECOLAB USA INC. 2024-05-02 US claimed
WO-2024081354-A1 ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING ECOLAB USA INC. (US) 2024-04-18 WO claimed
EP-4602020-A1 ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING Ecolab USA, Inc. (US) 2025-08-20 EP disclosed
US-20240141131-A1 ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING ECOLAB USA INC. 2024-05-02 US disclosed
WO-2024081354-A1 ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING ECOLAB USA INC. (US) 2024-04-18 WO disclosed
EP-3132796-A1 METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT Pericor Therapeutics, Inc. (US) 2017-02-22 EP disclosed
EP-2217565-B1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2013-05-22 EP disclosed